These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2330923)

  • 1. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
    Freedman MH; Grisaru D; Olivieri N; MacLusky I; Thorner PS
    Am J Dis Child; 1990 May; 144(5):565-9. PubMed ID: 2330923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary syndrome and intravenous high-dose desferrioxamine.
    Castriota Scanderbeg A; Izzi GC; Butturini A; Benaglia G
    Lancet; 1990 Dec; 336(8729):1511. PubMed ID: 1979119
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM; Neto EB; Simões BP; Zago MA
    Am J Hematol; 1998 Aug; 58(4):340-1. PubMed ID: 9692403
    [No Abstract]   [Full Text] [Related]  

  • 4. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 5. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and toxic properties of deferoxamine.
    Freedman MH; Bentur Y; Koren G
    Prog Clin Biol Res; 1989; 309():115-24. PubMed ID: 2675081
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity.
    Bentur Y; Koren G; Tesoro A; Carley H; Olivieri N; Freedman MH
    Clin Pharmacol Ther; 1990 Apr; 47(4):478-82. PubMed ID: 2328556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E; Marcopito LF; Zago MA
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
    Olivieri NF; Buncic JR; Chew E; Gallant T; Harrison RV; Keenan N; Logan W; Mitchell D; Ricci G; Skarf B
    N Engl J Med; 1986 Apr; 314(14):869-73. PubMed ID: 3485251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
    Galanello R; Kattamis A; Piga A; Fischer R; Leoni G; Ladis V; Voi V; Lund U; Tricta F
    Haematologica; 2006 Sep; 91(9):1241-3. PubMed ID: 16956824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desferrioxamine in acute iron poisoning.
    Chan KW; Bond M; Fernandez W
    Lancet; 1992 Jun; 339(8809):1601-2. PubMed ID: 1351566
    [No Abstract]   [Full Text] [Related]  

  • 14. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular toxicity of high-dose intravenous desferrioxamine.
    Davies SC; Marcus RE; Hungerford JL; Miller MH; Arden GB; Huehns ER
    Lancet; 1983 Jul; 2(8343):181-4. PubMed ID: 6135026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferoxamine-induced growth retardation in patients with thalassemia major.
    De Virgiliis S; Congia M; Frau F; Argiolu F; Diana G; Cucca F; Varsi A; Sanna G; Podda G; Fodde M
    J Pediatr; 1988 Oct; 113(4):661-9. PubMed ID: 3171791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Desferrioxamine in thalassemia].
    Biener R; Freundlich E; Rachmilewitz E
    Harefuah; 1983 May; 104(10):438-40. PubMed ID: 6629159
    [No Abstract]   [Full Text] [Related]  

  • 20. Current treatment of Cooley's anemia. Intravenous chelation therapy.
    Cohen AR; Martin M; Schwartz E
    Ann N Y Acad Sci; 1990; 612():286-92. PubMed ID: 2291556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.